221 related articles for article (PubMed ID: 9888463)
1. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.
Palma C; Nardelli F; Manzini S; Maggi CA
Br J Cancer; 1999 Jan; 79(2):236-43. PubMed ID: 9888463
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft.
Palma C; Bigioni M; Irrissuto C; Nardelli F; Maggi CA; Manzini S
Br J Cancer; 2000 Jan; 82(2):480-7. PubMed ID: 10646908
[TBL] [Abstract][Full Text] [Related]
3. Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis.
Akasaka Y; Abe K; Sato T; Inoue H
Neuropeptides; 2005 Oct; 39(5):467-74. PubMed ID: 16154193
[TBL] [Abstract][Full Text] [Related]
4. Effect of neurokinins on canine prostate cell physiology.
Walden PD; Marinese D; Srinivasan D; Tzoumaka E; Syyong HT; Ford AP; Bhattacharya A
Prostate; 2005 Jun; 63(4):358-68. PubMed ID: 15611996
[TBL] [Abstract][Full Text] [Related]
5. Role of neurogenic substance P in overexpression of alveolar macrophages' neurokinin 1 receptor in mice exposed to cigarette smoke.
Xu J; Xu F
Exp Lung Res; 2010 May; 36(4):243-54. PubMed ID: 20426532
[TBL] [Abstract][Full Text] [Related]
6. Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists.
Palma C; Nardelli F; Manzini S
Eur J Pharmacol; 1999 Jun; 374(3):435-43. PubMed ID: 10422788
[TBL] [Abstract][Full Text] [Related]
7. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
8. Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells.
Cooke HJ; Fox P; Alferes L; Fox CC; Wolfe SA
Can J Physiol Pharmacol; 1998 Feb; 76(2):188-93. PubMed ID: 9635159
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
10. Localization of neurokinin 1 receptor (NK1R) immunoreactivity in rat esophagus.
Kuramoto H; Oomori Y; Murabayashi H; Kadowaki M; Karaki S; Kuwahara A
J Comp Neurol; 2004 Oct; 478(1):11-21. PubMed ID: 15334646
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
12. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
13. [Substance P up-regulates the TGF-beta 1 mRNA expression of human dermal fibroblasts in vitro].
Hu D; Chen B; Zhu X; Tao K; Tang C; Wang J
Zhonghua Zheng Xing Wai Ke Za Zhi; 2002 Jul; 18(4):234-6. PubMed ID: 12382579
[TBL] [Abstract][Full Text] [Related]
14. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-1 receptor (NK-1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P.
Goode T; O'Connor T; Hopkins A; Moriarty D; O'Sullivan GC; Collins JK; O'Donoghue D; Baird AW; O'Connell J; Shanahan F
J Cell Physiol; 2003 Oct; 197(1):30-41. PubMed ID: 12942538
[TBL] [Abstract][Full Text] [Related]
16. Tachykinin activation of human monocytes from patients with rheumatoid arthritis: in vitro and ex-vivo effects of cyclosporin A.
Lavagno L; Bordin G; Colangelo D; Viano I; Brunelleschi S
Neuropeptides; 2001 Apr; 35(2):92-9. PubMed ID: 11384204
[TBL] [Abstract][Full Text] [Related]
17. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines.
Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Piruat JI
Neuropeptides; 2005 Aug; 39(4):427-32. PubMed ID: 15939468
[TBL] [Abstract][Full Text] [Related]
18. Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism.
Salthun-Lassalle B; Traver S; Hirsch EC; Michel PP
Mol Pharmacol; 2005 Nov; 68(5):1214-24. PubMed ID: 16077032
[TBL] [Abstract][Full Text] [Related]
19. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
20. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
